World Health Organ Tech Rep Ser. 2016(998):1-34.
The WHO Expert Committee on Drug Dependence (ECDD) is responsible for assessing psychoactive substances for possible control under the international drug control conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm potential of each substance under review. After the ECDD advises the Director-General of WHO as to whether to schedule or to amend the scheduling status of a substance, the Director-General will, as appropriate, communicate the recommendations to the United Nations Secretary-General. The Secretary-General communicates the advice to the Commission on Narcotic Drugs (CND), as appropriate. This report presents the recommendations of the thirty-seventh meeting of the WHO Expert Committee on Drug Dependence. The report summarizes the review of nine substances and the ECDD’s recommendations for the scheduling of seven substances. The report also provides updates on ketamine and cannabis, as requested byresolutions of the Commission on Narcotic Drugs. It contains updates on the work of international bodies concerned with controlled substances, as well as summaries of the follow-up discussions on recommendations made at the previous ECDD meeting, and on the discussions on criteria for assessing new psychoactive substances and on terminology.
世界卫生组织药物依赖性专家委员会（ECDD）负责评估精神活性物质，以确定是否可根据国际药物管制公约进行管制。ECDD审查每种受审查物质的治疗用途、滥用和依赖可能性，以及对公众健康和社会造成危害的可能性。在ECDD就某一物质是否列入附表或修订其附表状态向世卫组织总干事提供建议后，总干事将酌情把这些建议传达给联合国秘书长。秘书长再酌情将这些建议传达给麻醉药品委员会（CND）。本报告介绍了世界卫生组织药物依赖性专家委员会第三十七次会议的建议。该报告总结了对九种物质的审查情况以及ECDD对七种物质列入附表的建议。该报告还应麻醉药品委员会决议要求，提供了氯胺酮和大麻的最新情况。报告包含了与受管制物质有关的国际机构工作的最新情况，以及对上一次ECDD会议所提建议后续讨论情况的总结，还有关于评估新型精神活性物质标准和术语的讨论情况。
